Literature DB >> 18511936

Targeting the oncogene and kinome chaperone CDC37.

Phillip J Gray1, Thomas Prince, Jinrong Cheng, Mary Ann Stevenson, Stuart K Calderwood.   

Abstract

CDC37 is a molecular chaperone that physically stabilizes the catalytic domains found in protein kinases and is therefore a wide-spectrum regulator of protein phosphorylation. It is also an overexpressed oncoprotein that mediates carcinogenesis by stabilizing the compromised structures of mutant and/or overexpressed oncogenic kinases. Recent work shows that such dependency of malignant cells on increased CDC37 expression is a vulnerability that can be targeted in cancer by agents that deplete or inhibit CDC37. CDC37 is thus a candidate for broad-spectrum molecular cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18511936      PMCID: PMC2779120          DOI: 10.1038/nrc2420

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  39 in total

1.  Definition of protein kinase sequence motifs that trigger high affinity binding of Hsp90 and Cdc37.

Authors:  Thomas Prince; Robert L Matts
Journal:  J Biol Chem       Date:  2004-07-17       Impact factor: 5.157

Review 2.  Hsp90 and Cdc37 -- a chaperone cancer conspiracy.

Authors:  Laurence H Pearl
Journal:  Curr Opin Genet Dev       Date:  2005-02       Impact factor: 5.578

3.  Cdk2: a genuine protein kinase client of Hsp90 and Cdc37.

Authors:  Thomas Prince; Liang Sun; Robert L Matts
Journal:  Biochemistry       Date:  2005-11-22       Impact factor: 3.162

4.  Domain-mediated dimerization of the Hsp90 cochaperones Harc and Cdc37.

Authors:  John Roiniotis; Paul Masendycz; Sokwei Ho; Glen M Scholz
Journal:  Biochemistry       Date:  2005-05-03       Impact factor: 3.162

5.  Cdc37 maintains cellular viability in Schizosaccharomyces pombe independently of interactions with heat-shock protein 90.

Authors:  Emma L Turnbull; Ina V Martin; Peter A Fantes
Journal:  FEBS J       Date:  2005-08       Impact factor: 5.542

Review 6.  HSP90 and the chaperoning of cancer.

Authors:  Luke Whitesell; Susan L Lindquist
Journal:  Nat Rev Cancer       Date:  2005-10       Impact factor: 60.716

7.  Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas.

Authors:  Mary Ann Thompson; Jennifer Stumph; Sarah E Henrickson; Andreas Rosenwald; Qifu Wang; Sandy Olson; Stephen J Brandt; Jeremy Roberts; Xueqiong Zhang; Yu Shyr; Marsha C Kinney
Journal:  Hum Pathol       Date:  2005-05       Impact factor: 3.466

8.  Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4.

Authors:  L Stepanova; X Leng; S B Parker; J W Harper
Journal:  Genes Dev       Date:  1996-06-15       Impact factor: 11.361

9.  Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1.

Authors:  J Zou; Y Guo; T Guettouche; D F Smith; R Voellmy
Journal:  Cell       Date:  1998-08-21       Impact factor: 41.582

10.  Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.

Authors:  Yuta Katayama; Akira Sakai; Yoshiko Okikawa; Naohide Oue; Hideki Asaoku; Ayako Sasaki; Fumio Imanaka; Takako Tsujimoto; Yasuo Takimoto; Rie Masuda; Nanae Nakaju; Takemi Otsuki; Wataru Yasui; Akiro Kimura
Journal:  Int J Oncol       Date:  2004-09       Impact factor: 5.650

View more
  57 in total

Review 1.  Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come.

Authors:  Ayesha Murshid; Jianlin Gong; Mary Ann Stevenson; Stuart K Calderwood
Journal:  Expert Rev Vaccines       Date:  2011-11       Impact factor: 5.217

2.  Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes.

Authors:  Hiroyuki Takai; Yihu Xie; Titia de Lange; Nikola P Pavletich
Journal:  Genes Dev       Date:  2010-08-27       Impact factor: 11.361

3.  The chaperones Hsp90 and Cdc37 mediate the maturation and stabilization of protein kinase C through a conserved PXXP motif in the C-terminal tail.

Authors:  Christine M Gould; Natarajan Kannan; Susan S Taylor; Alexandra C Newton
Journal:  J Biol Chem       Date:  2008-12-17       Impact factor: 5.157

Review 4.  Hsp90 in Cancer: Transcriptional Roles in the Nucleus.

Authors:  Stuart K Calderwood; Len Neckers
Journal:  Adv Cancer Res       Date:  2015-10-12       Impact factor: 6.242

5.  Systematic identification of the HSP90 candidate regulated proteome.

Authors:  Zhixiang Wu; Amin Moghaddas Gholami; Bernhard Kuster
Journal:  Mol Cell Proteomics       Date:  2012-02-14       Impact factor: 5.911

6.  In vivo identification of regulators of cell invasion across basement membranes.

Authors:  David Q Matus; Xiao-Yan Li; Sarah Durbin; Daniel Agarwal; Qiuyi Chi; Stephen J Weiss; David R Sherwood
Journal:  Sci Signal       Date:  2010-05-04       Impact factor: 8.192

Review 7.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

Review 8.  Cdc37 as a co-chaperone to Hsp90.

Authors:  Stuart K Calderwood
Journal:  Subcell Biochem       Date:  2015

9.  Canonical and kinase activity-independent mechanisms for extracellular signal-regulated kinase 5 (ERK5) nuclear translocation require dissociation of Hsp90 from the ERK5-Cdc37 complex.

Authors:  Tatiana Erazo; Ana Moreno; Gerard Ruiz-Babot; Arantza Rodríguez-Asiain; Nicholas A Morrice; Josep Espadamala; Jose R Bayascas; Nestor Gómez; Jose M Lizcano
Journal:  Mol Cell Biol       Date:  2013-02-19       Impact factor: 4.272

Review 10.  Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update.

Authors:  Daniel R Ciocca; Andre Patrick Arrigo; Stuart K Calderwood
Journal:  Arch Toxicol       Date:  2012-08-11       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.